AR082218A1 - Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion - Google Patents

Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion

Info

Publication number
AR082218A1
AR082218A1 ARP110102539A ARP110102539A AR082218A1 AR 082218 A1 AR082218 A1 AR 082218A1 AR P110102539 A ARP110102539 A AR P110102539A AR P110102539 A ARP110102539 A AR P110102539A AR 082218 A1 AR082218 A1 AR 082218A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
formula
halogen
compound
Prior art date
Application number
ARP110102539A
Other languages
English (en)
Original Assignee
Medeia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeia Therapeutics Ltd filed Critical Medeia Therapeutics Ltd
Publication of AR082218A1 publication Critical patent/AR082218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los derivados de arilamida de la fórmula (1) tienen propiedades antiandrogénicas. La presente también se refiere a compuestos de la fórmula (1) para utilizar como un medicamento y a composiciones farmacéuticas que los contienen y a su preparación.Reivindicación 1: Un derivado de arilamida que tiene la fórmula (1) y estereoisómeros y sus sales farmacéuticamente aceptables; donde R’ y R’’ cada una se selecciona de modo independiente del grupo que consta de H y alquilo; z es un número entero 0 a 3; R1 se selecciona del grupo que consta de H, halógeno, (per)haloalquilo, hidroxi y (CH2)nCHO, donde n es un número entero 0 - 6; R2 se selecciona del grupo que consta de H, alquilo, halógeno, trifluorometilo, (halo)alquilo, hidroxi y (CH2)nCHO, donde n es un número entero 0 - 6; R3 se selecciona del grupo que consta de NO2, CN, COR, COOH, CONHR, donde R es hidrógeno o alquilo; halógeno e hidroxi; R4 y R5 cada una se selecciona de modo independiente del grupo que consta de H, alquilo y halógeno, o R4 y R5 forman en conjunto con los átomos de carbono, a los cuales están unidos, un anillo aromático o heteroaromático, alifático, heteroalifático sustituido o no sustituido; R6 - R10 cada una se selecciona de modo independiente del grupo que consta de H, alquilo, halógeno, (per)haloalquilo, CN, NO2, COR, COOH, CONHR, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, donde R es tal como se definió anteriormente; NHCSCH3, alquiltio, alquilsulfinilo y alquilsulfonilo, con la condición de que al menos uno de R6 - R10 sea distinto de H; o dos adyacentes R6 - R10 forman con los átomos de carbono, a los cuales están unidos, un anillo aromático o heteroaromático, alifático, heteroalifático sustituido o no sustituido; X se selecciona del grupo que consta de O, S, S(O), SO2, NR12, donde R12 se selecciona del grupo que consta de H, alquilo, COCH3 y COR, donde R es tal como se definió anteriormente; CH2 y CO; o cuando z es 0, entonces X puede ser N y forma en conjunto con R11 un anillo heterocíclico seleccionado del grupo que consta de morfolina, 1,2,4-triazol, imidazol e imidazol N-sustituido; y R11, cuando no forma un anillo con X tal como se definió anteriormente, se selecciona del grupo que consta de alquilo, alquenilo, (per)haloalquilo, haloalquenilo, alquilo-CN y un arilo, heteroarilo, anillo alifático o heteroalifático de 5 - 7 miembros opcionalmente sustituido con 1 - 5 sustituyentes seleccionados del grupo que consta de alquilo, halógeno, (per)haloalquilo, CN, NO2, COR, COOH, CONHR, NR2, NHCOCH3, NHCOCF3, NHCOR, NHCONHR, NHCOOR, OCONHR, NHSO2R, donde R es tal como se definió anteriormente; NHCSCH3, alquiltio, alquilsulfinilo y alquilsulfonilo. Reivindicación 18: Un proceso para la preparación de un derivado de arilamida de la fórmula (1) tal como se definió en la reivindicación 1, donde X es O, SO o SO2, que comprende hacer reaccionar un compuesto epoxi de la fórmula (2), donde R1 - R10 son tal como se definieron en la reivindicación 1, con un compuesto de la fórmula R11-(CR’R’’)z-X’H, donde R11, R’, R’’ y z son tal como se definieron en la reivindicación 1 y X’ es O ó S, para obtener un compuesto de la fórmula (1), donde X es O ó S, y, si se desea, la oxidación del compuesto obtenido para obtener un compuesto de la fórmula (1), donde X es SO o SO2.
ARP110102539A 2010-07-15 2011-07-14 Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion AR082218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20105806A FI20105806A0 (fi) 2010-07-15 2010-07-15 Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia

Publications (1)

Publication Number Publication Date
AR082218A1 true AR082218A1 (es) 2012-11-21

Family

ID=42555499

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102539A AR082218A1 (es) 2010-07-15 2011-07-14 Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion

Country Status (18)

Country Link
US (1) US8816119B2 (es)
EP (1) EP2593424B1 (es)
JP (1) JP5990833B2 (es)
KR (1) KR101928375B1 (es)
CN (1) CN102985403B (es)
AR (1) AR082218A1 (es)
AU (1) AU2011278201B2 (es)
BR (1) BR112013000783B1 (es)
CA (1) CA2804765C (es)
EA (1) EA022619B1 (es)
ES (1) ES2750309T3 (es)
FI (1) FI20105806A0 (es)
MX (1) MX2013000474A (es)
NZ (1) NZ605636A (es)
SG (1) SG187049A1 (es)
TW (1) TWI542343B (es)
WO (1) WO2012007644A1 (es)
ZA (1) ZA201300300B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104831A1 (en) * 2012-01-13 2013-07-18 Medeia Therapeutics Ltd Arylamide derivatives having antiandrogenic properties
WO2016079521A1 (en) * 2014-11-20 2016-05-26 University College Cardiff Consultants Limited Androgen receptor modulators and their use as anti-cancer agents
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20170140291A (ko) 2015-04-21 2017-12-20 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX2017013565A (es) 2015-04-21 2018-02-19 Gtx Inc Ligandos degradadores selectivos del receptor androgénico (sard) y sus métodos uso.
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0099165A1 (en) * 1982-03-23 1984-01-25 Imperial Chemical Industries Plc Triazole and imidazole compounds, process for their preparation and their use as fungicides and plant growth regulators, and intermediates for their synthesis
ZA831466B (en) * 1982-03-23 1984-10-31 Ici Plc Heterocyclic compounds
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
US6160011A (en) * 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1991523B1 (en) * 2006-03-03 2012-08-15 Orion Corporation Selective androgen receptor modulators
TW200812962A (en) 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
CN101516835A (zh) * 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
US20090156614A1 (en) 2006-07-19 2009-06-18 Dalton James T Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
AU2007313295A1 (en) * 2006-10-18 2008-04-24 Merck Sharp & Dohme Corp. 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
MX2010009162A (es) * 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
EP2424853B1 (en) * 2009-04-10 2018-09-19 Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. Non-steroidal compounds for androgen receptor modulation, processes for the preparation and uses thereof

Also Published As

Publication number Publication date
CN102985403A (zh) 2013-03-20
US20130109750A1 (en) 2013-05-02
TWI542343B (zh) 2016-07-21
FI20105806A0 (fi) 2010-07-15
JP2013532178A (ja) 2013-08-15
EP2593424B1 (en) 2019-08-28
ZA201300300B (en) 2013-09-25
TW201208669A (en) 2012-03-01
EA022619B1 (ru) 2016-02-29
EP2593424A1 (en) 2013-05-22
KR20130079479A (ko) 2013-07-10
EA201390008A1 (ru) 2013-05-30
SG187049A1 (en) 2013-02-28
KR101928375B1 (ko) 2018-12-12
CA2804765C (en) 2018-08-07
US8816119B2 (en) 2014-08-26
BR112013000783B1 (pt) 2022-01-25
AU2011278201A1 (en) 2013-01-31
BR112013000783A2 (pt) 2020-11-03
CN102985403B (zh) 2016-03-23
AU2011278201B2 (en) 2014-08-21
NZ605636A (en) 2014-05-30
CA2804765A1 (en) 2012-01-19
WO2012007644A1 (en) 2012-01-19
MX2013000474A (es) 2013-05-17
JP5990833B2 (ja) 2016-09-14
ES2750309T3 (es) 2020-03-25

Similar Documents

Publication Publication Date Title
AR082218A1 (es) Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion
JP2016531121A5 (es)
JP2013531029A5 (es)
JP2019518766A5 (es)
JP2014528467A5 (es)
JP2016505586A5 (es)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
JP2015522650A5 (es)
JP2017132814A5 (es)
JP2016506960A5 (es)
HRP20170104T1 (hr) Derivati tipa azaindazola ili diazaindazola za liječenje boli
JP2016506961A5 (es)
JP2017528467A5 (es)
WO2014140862A3 (en) Pyrrolobenzodiazepines and conjugates thereof
JP2018536648A5 (es)
JP2014518882A5 (es)
EA201591000A1 (ru) Пирролобензодиазепины
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
WO2012003405A4 (en) Sgc stimulators
JP2016537382A5 (es)
JP2016506958A5 (es)
ATE259803T1 (de) 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
JP2015535847A5 (es)
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.

Legal Events

Date Code Title Description
FG Grant, registration